Name | Value |
---|---|
MEASURE TITLE | Venous Thromboembolism Patients with Anticoagulation Overlap Therapy |
CMS ID | CMS73v5 |
VERSION NUMBER | 5.1.000 |
DEVELOPER | The Joint Commission |
STEWARD | The Joint Commission |
COPYRIGHT | Measure specifications are in the Public Domain.LOINC(R) is a registered trademark of the Regenstrief Institute.This material contains SNOMED Clinical Terms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology Standards Development Organization. All rights reserved. |
VALUE SETS |
|
GUID | 6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7 |
NQF NUMBER | 0373 |
DESCRIPTION | This measure assesses the number of patients diagnosed with confirmed VTE who received an overlap of parenteral (intravenous [IV] or subcutaneous [subcu]) anticoagulation and warfarin therapy. For patients who received less than five days of overlap therapy, they should be discharged on both medications or have a reason for discontinuation of overlap therapy. Overlap therapy should be administered for at least five days with an international normalized ratio (INR) greater than or equal to 2 prior to discontinuation of the parenteral anticoagulation therapy, discharged on both medications or have a reason for discontinuation of overlap therapy. |
CATEGORY | Medication |
IDENTIFIER | 73 |
STATUS | COMPLETED |
TYPE | PROCESS |
MEASURE SET | FY 2014 EH |